Details for Patent: 8,182,838

Which drugs does patent 8,182,838 protect, and when does it expire?

Patent 8,182,838 protects SEEBRI and UTIBRON and is included in two NDAs.

This patent has sixty-three patent family members in twenty-three countries.

Summary for Patent: 8,182,838

Title:	Dry powder composition comprising co-jet milled particles for pulmonary inhalation
Abstract:	The present invention relates to particles and to methods of making particles. In particular, the invention relates to methods of making composite active particles comprising a pharmaceutically active material for pulmonary inhalation, the method comprising a jet milling process.
Inventor(s):	Morton; David (Chippenham, GB), Staniforth; John (Chippenham, GB)
Assignee:	Vectura Limited (Chippenham, GB)
Application Number:	10/571,146
Patent Claim Types: see list of patent claims	Use; Composition; Delivery;

Drugs Protected by US Patent 8,182,838

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis	SEEBRI	glycopyrrolate	POWDER;INHALATION	207923-001	Oct 29, 2015		DISCN	Yes	No			Y
Novartis	UTIBRON	glycopyrrolate; indacaterol maleate	POWDER;INHALATION	207930-001	Oct 29, 2015		DISCN	Yes	No			Y

Foreign Priority and PCT Information for Patent: 8,182,838

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0321607.4	Sep 15, 2003

PCT Information
PCT Filed	September 15, 2004	PCT Application Number:	PCT/GB2004/003996
PCT Publication Date:	March 24, 2005	PCT Publication Number:	WO2005/025536

International Family Members for US Patent 8,182,838

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	535233
Australia	2004228757
Australia	2004231342
Australia	2004271779
Australia	2004271783